viewScancell Holdings PLC

Scancell Holdings inks drug delivery technology deal

It has exercised an option on TriGrid, which was developed by Ichor Medical Systems

woman at a microscope
The new technology will be used in an upcoming cancer trial

Immunotherapy specialist Scancell Holdings PLC (LON:SCLP) has exercised an option to in-licence delivery technology for its lead drug candidate.

It has inked a deal with Ichor Medical Systems, which has developed the TriGrid 2.0 electroporation system.

READ: Scancell receives European patent protection for immunotherapy platform

TriGrid will now be used in harness with Scancell's SCIB1 vaccine, a melanoma treatment.

Specifically, it will be deployed in an upcoming Phase II clinical trial in which the Scancell drug candidate is being deployed alongside a checkpoint inhibitor.

Vital component 

Chief executive Cliff Holloway said: "Ichor's proprietary TriGrid electroporation delivery system is a vital component for the delivery of our SCIB1 vaccine and in particular, to our upcoming US clinical study of SCIB1 in combination with a checkpoint inhibitor, which is expected to commence later this year.

“The exercise of this commercial option is a further key milestone in bringing this important new treatment to the market."

The company said an option fee will be paid. Ichor will receive further cash once certain developmental milestones are passed.

Scancell has also agreed an extension for the exercise of share options granted to Ichor as part of the initial deal.

Quick facts: Scancell Holdings PLC

Price: 17 GBX

Market: LSE
Market Cap: £108.52 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...


Scancell Holdings awarded funds from Innovate UK for COVID-19 vaccine

Scancell Holdings' (LON:SCLP) Dr Cliff Holloway talks to Proactive London's Katie Pilbeam after being awarded funds from Innovate UK to produce a COVID-19 vaccine. Holloway explains how the company is using their immunotherapies knowledge which is used in their cancer research projects to...

3 weeks, 6 days ago

2 min read